Wealthsource Partners LLC raised its stake in Novartis AG (NYSE:NVS) by 16.3% during the first quarter, Holdings Channel reports. The institutional investor owned 3,222 shares of the company’s stock after buying an additional 451 shares during the period. Wealthsource Partners LLC’s holdings in Novartis AG were worth $239,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Marshall Wace LLP increased its stake in Novartis AG by 10.1% in the fourth quarter. Marshall Wace LLP now owns 494,535 shares of the company’s stock valued at $36,022,000 after buying an additional 45,452 shares in the last quarter. Davis Selected Advisers acquired a new stake in Novartis AG during the fourth quarter valued at about $18,769,000. Dodge & Cox acquired a new stake in Novartis AG during the fourth quarter valued at about $3,330,137,000. AT Bancorp increased its stake in Novartis AG by 4.2% in the first quarter. AT Bancorp now owns 11,690 shares of the company’s stock valued at $868,000 after buying an additional 470 shares in the last quarter. Finally, Oxford Asset Management increased its stake in Novartis AG by 223.5% in the fourth quarter. Oxford Asset Management now owns 23,837 shares of the company’s stock valued at $1,736,000 after buying an additional 16,469 shares in the last quarter. Institutional investors own 11.37% of the company’s stock.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Shares of Novartis AG (NYSE NVS) opened at 81.44 on Tuesday. The firm has a market capitalization of $192.65 billion, a PE ratio of 30.62 and a beta of 0.76. The company has a 50-day moving average of $80.28 and a 200 day moving average of $75.35. Novartis AG has a 12-month low of $66.93 and a 12-month high of $83.58.

Novartis AG (NYSE:NVS) last announced its earnings results on Tuesday, April 25th. The company reported $1.13 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.03. Novartis AG had a return on equity of 15.46% and a net margin of 13.10%. The company had revenue of $11.54 billion during the quarter, compared to analyst estimates of $11.59 billion. During the same period last year, the company posted $1.17 earnings per share. The firm’s quarterly revenue was down .5% compared to the same quarter last year. On average, analysts predict that Novartis AG will post $4.69 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Wealthsource Partners LLC Boosts Position in Novartis AG (NVS)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/06/20/wealthsource-partners-llc-boosts-position-in-novartis-ag-nvs.html.

NVS has been the subject of several research reports. Vetr upgraded shares of Novartis AG from a “buy” rating to a “strong-buy” rating and set a $85.25 price objective for the company in a research note on Wednesday, March 8th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research note on Thursday, March 23rd. BNP Paribas downgraded shares of Novartis AG from a “neutral” rating to an “underperform” rating in a research note on Tuesday, March 7th. Barclays PLC initiated coverage on shares of Novartis AG in a research note on Tuesday, March 7th. They set an “underweight” rating for the company. Finally, Liberum Capital initiated coverage on shares of Novartis AG in a research note on Thursday, March 9th. They set a “buy” rating for the company. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $83.12.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.